Sanofi’s Gene Therapy for Wet AMD Earns FDA Fast Track Designation

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAR402663, Sanofi’s investigational gene therapy for neovascular age-related macular degeneration (AMD). As seen in a report, this is a significant milestone in the development of innovative treatments for vision-threatening retinal diseases.

What Is SAR402663?

SAR402663 is a one-time intravitreal gene therapy designed to treat neovascular (or “wet”) AMD. This form of AMD is characterized by the growth of abnormal blood vessels beneath the retina, leading to leakage, retinal damage, and progressive vision loss. The therapy delivers genetic material encoding soluble FLT01, a protein engineered to inhibit vascular endothelial growth factor (VEGF)—a key driver of abnormal blood vessel growth in wet AMD.

By targeting VEGF, SAR402663 aims to:

Suppress abnormal blood vessel formation
Reduce vascular leakage
Minimize retinal damage
Potentially eliminate the need for frequent intravitreal injections

Sanofi is currently evaluating SAR402663 in a Phase 1/2 clinical trial (ClinicalTrials.gov Identifier: NCT06660667).

Why Fast Track Matters

The FDA’s Fast Track designation is reserved for therapies that address serious conditions and demonstrate the potential to meet unmet medical needs. This designation facilitates more frequent communication with the FDA, eligibility for accelerated approval, and priority review—ultimately aiming to bring promising treatments to patients more quickly.

The Burden of Neovascular AMD

Age-related macular degeneration is a progressive retinal disease affecting approximately 200 million people globally. The neovascular form, though less common than dry AMD, is more severe and can lead to rapid vision loss and even blindness if untreated.

In the U.S. alone, more than one million people live with neovascular AMD, and over six million are affected worldwide. The condition significantly impacts quality of life, interfering with daily activities such as reading, driving, and recognizing faces.

Sanofi’s Broader Commitment to Neurology and Ophthalmology

Sanofi is actively advancing research in neuroinflammatory and neurodegenerative diseases, including:

Multiple sclerosis (MS)
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Alzheimer’s disease (AD)
Parkinson’s disease (PD)
Age-related macular degeneration (AMD)

The company’s investment in ophthalmology reflects a strategic expansion into areas of high unmet need, particularly where retinal diseases intersect with immune system dysfunction.

About Sanofi

Sanofi is a research-driven, AI-powered biopharmaceutical company committed to improving lives through scientific innovation. With a robust pipeline and a focus on immunology, Sanofi develops medicines and vaccines that serve millions globally. The company is publicly traded on EURONEXT (SAN) and NASDAQ (SNY).